In this interview, Dr. Neil Sheppard, director of the Therapeutic Innovation in Natural Killer cells (THINK) lab at the ...

The main market opportunities lie in developing CD40-targeting therapies, including agonists for cancer immunotherapy and antagonists for autoimmune diseases. Innovations focus on overcoming systemic ...

B7-H4-targeted immunotherapies offer market opportunities in developing treatments for cancers with high B7-H4 expression, including ovarian, breast, and endometrial cancers. Utilizing diverse ...

An adjuvant is one of those key components. Added to a vaccine, an adjuvant can enhance the body's immune response, making ...